Johnson & Johnson

- No new fundraising through debt or equity is currently planned. - Johnson & Johnson ended Q3 2023 with approximately $24 billion in cash and marketable securities and $18 billion of debt, resulting in a net debt position of $6 billion. - The company executed the Kenvue separation within targeted timeframe and under budget, reducing Johnson & Johnson’s outstanding shares by approximately 7%. - They retained about 180 million shares of Kenvue stock to provide future cash proceeds. - Capital allocation plans include using strong credit profile and robust free cash flow to: - Prioritize strategic business development initiatives - Increase dividends annually - Execute share repurchases when appropriate - There is no mention of plans for new debt or equity fundraising through 2024 in the current reports.

- Johnson & Johnson is progressively adding manufacturing capacity for Carvykti, including ramping up the original site in New Jersey, establishing a manufacturing site in Belgium, leveraging excess Novartis capacity, and building a new factory in the Netherlands for lentivirus component production expected next year. - The company is implementing a restructuring program in MedTech, especially Orthopedics, aiming to simplify and focus operations with an expected completion by the end of 2025. - Free cash flow was approximately $12 billion year-to-date through Q3 2023, supporting strategic and disciplined capital allocation including business development initiatives for inorganic growth and share repurchases. - Planned investments in 2024 include advancing pipeline programs (innovation in pulse field ablation, Abiomed, surgical robotics), and multiple clinical development programs like Anthem and ICONIC for oral peptide J&J-2113 expected to start soon. - No specific large-scale future capital expenditure amounts were detailed, but capacity expansions and clinical program investments indicate ongoing strategic capital commitments.

- MedTech procedural growth expected at 5% to 7% in 2024, maintaining elevated levels seen recently (Page 5). - Positive outlook for MedTech driven by new product launches (e.g., PFA catheter in Europe in 2024) and increased procedural volumes (Page 5). - Immunology business, especially Tremfya, showing strong growth (25.1%) with expected further expansion due to additional indications like ulcerative colitis and Crohn's disease (Page 5). - Pharmaceuticals target $57 billion revenue by 2025, supported by growth in key assets (Tremfya, Erleada, Uptravi, Darzalex) and pipeline progress (Page 4). - CAR-T therapy Carvykti showing strong demand with manufacturing capacity ramping up; expected continuous sales improvement into 2024 (Page 4). - Orthopedics facing seasonality and restructuring but committed to growth by focusing on high-growth segments and portfolio improvements (Page 3). - China remains a key growth driver, despite some headwinds from value-based procurement policies (Page 5).

- Johnson & Johnson raised full-year 2023 operational sales growth guidance to 8.5%-9%, up $600 million at midpoint. - Adjusted pre-tax operating margin expected to improve by approximately 50 basis points versus 2022. - Adjusted reported earnings per share (EPS) guidance increased to a range of $10.02 to $10.08, reflecting 12.5% growth at midpoint. - Full impact of ~191 million net share reduction reflected in 2024 financials, aiding EPS. - For 2024, margins likely stable around 2023 levels; no specific margin guidance yet. - Continued growth driven by Innovative Medicines’ key brands, new product launches (e.g., Tecvayli, Talvey), and pipeline advancements. - MedTech procedures expected to remain consistent with 2023. - Biosimilar entry of Stelara in U.S. not expected in 2024, supporting pharma unit growth. - Overall, confident in delivering strong top-line growth and margin progress into 2024 and beyond.

The provided document excerpt does not contain specific information regarding current, expected, or pending orderbook/orders for Johnson & Johnson or its subdivisions. The transcript mainly discusses financial performance, product portfolios, pipeline updates, and litigation status, without mentioning orderbook or pending orders details. If you need information on J&J's orderbook or pending orders, please provide relevant sections or specify a different document containing that data.